UDK: УДК 615.31:547:616.379-008.64-085.252

COMPARATIVE EFFICACY OF А MEMBER OF THE NEW CLASS OF ORAL BLOOD GLUCOSE-LOWERING AGENT «BATION» (ANTIBODIES TO THE INSULIN RECEPTOR) IN PATIENTS WITH TYPE II DIABETES

V. I. Petrov, N. V. Rogova, A. U. Ryazanova, S. A. Sergeeva, M. V. Katchanova, U. A. Zabolotneva, O. I. Epshtein

Кафедра клинической фармакологии ВолГМУ

Abstract

Bation (antibodies to the C-final fragment of в-subunit insulin receptor in extremely low doses, a mixture of homoeopathic dilutions of С12+С30+С200, «Scientific and Industrial Manufacturer «Materia Medica Holding», Ltd, Russia), is a novel drug developed to treat type II diabetes. A conducted clinical trial showed that the drug was effective and safe when used in patients with type II diabetes of moderate severity. Taking into account the effectiveness and safety of this drug, Bation can be recommended as a prescription medication for patients with moderate forms of type II diabetes when disturbance of carbohydrate metabolism is moderately manifested.

Keywords

Diabetes mellitus, treatment of type II diabetes, the new class of oral blood glucose-lowering agents, Bation, antibodies to the insulin receptor.

Contacts

Рогова Наталья Вячеславовна - к.м.н., доцент кафедры клинической фармакологии и интенсивной терапии с курсами клинической фармакологии ФУВ, клинической аллергологии ФУВ, восстановительной терапии и курортологии ФУВ ВолГМУ, (8442) 43-30-60, 43-60-36, nvrog